Header Logo

Connection

Anthony Rothschild to Antidepressive Agents

Back to Details
This is a "connection" page, showing publications Anthony Rothschild has written about Antidepressive Agents.
Anthony Rothschild
Connection Strength
5.328
Antidepressive Agents
  1. Rothschild AJ. Why Is There No Food and Drug Administration-Approved Medication for Major Depression With Psychotic Features? J Clin Psychopharmacol. 2021 Jul-Aug 01; 41(4):359-361.
    View in: PubMed
    Score: 0.660
  2. Smith EG, Deligiannidis KM, Ulbricht CM, Landolin CS, Patel JK, Rothschild AJ. Antidepressant augmentation using the N-methyl-D-aspartate antagonist memantine: a randomized, double-blind, placebo-controlled trial. J Clin Psychiatry. 2013 Oct; 74(10):966-73.
    View in: PubMed
    Score: 0.386
  3. Rothschild AJ. Challenges in the treatment of major depressive disorder with psychotic features. Schizophr Bull. 2013 Jul; 39(4):787-96.
    View in: PubMed
    Score: 0.374
  4. Glezer A, Byatt N, Cook R, Rothschild AJ. Polypharmacy prevalence rates in the treatment of unipolar depression in an outpatient clinic. J Affect Disord. 2009 Sep; 117(1-2):18-23.
    View in: PubMed
    Score: 0.277
  5. Rothschild AJ. The Rothschild Scale for Antidepressant Tachyphylaxis: reliability and validity. Compr Psychiatry. 2008 Sep-Oct; 49(5):508-13.
    View in: PubMed
    Score: 0.266
  6. Butterfield NN, Luzon Rosenblut C, Fava M, Correll CU, Rothschild AJ, Murrough JW, Mathew SJ, Beatch GN, Grayson C, Harden C, Qian J, McIntosh J, Namdari R, Kenney C. Azetukalner, a Novel KV7 Potassium Channel Opener, in Adults With Major Depressive Disorder: A Randomized Clinical Trial. JAMA Netw Open. 2025 May 01; 8(5):e2514278.
    View in: PubMed
    Score: 0.215
  7. Carter E, Banerjee S, Alexopoulos GS, Bingham KS, Marino P, Meyers BS, Mulsant BH, Neufeld NH, Rothschild AJ, Voineskos AN, Whyte EM, Flint AJ. Prediction of remission of pharmacologically treated psychotic depression: A machine learning approach. J Affect Disord. 2025 Jul 15; 381:291-297.
    View in: PubMed
    Score: 0.214
  8. Rothschild AJ. Question: How Should I Switch From One Selective Serotonin Reuptake Inhibitor (SSRI) or Serotonin and Norepinephrine Reuptake Inhibitor (SNRI) to Another SSRI or SNRI in a Patient With Major Depressive Disorder? J Clin Psychopharmacol. 2024 Sep-Oct 01; 44(5):531-532.
    View in: PubMed
    Score: 0.205
  9. Cintr?n Pastrana MA, Irizarry Flores JC, Rothschild AJ. Challenges in the Treatment of Psychotic Bipolar Depression. J Clin Psychopharmacol. 2024 Jul-Aug 01; 44(4):407-412.
    View in: PubMed
    Score: 0.203
  10. Forester BP, Parikh SV, Weisenbach S, Ajilore O, Vahia I, Rothschild AJ, Thase ME, Dunlop BW, DeBattista C, Conway CR, Shelton RC, Macaluso M, Li J, Traxler P, Logan J, Brown L, Dechairo B, Greden JF. Combinatorial Pharmacogenomic Testing Improves Outcomes for Older Adults With Depression. Am J Geriatr Psychiatry. 2020 09; 28(9):933-945.
    View in: PubMed
    Score: 0.153
  11. Shelton RC, Parikh SV, Law RA, Rothschild AJ, Thase ME, Dunlop BW, DeBattista C, Conway CR, Forester BP, Macaluso M, Hain DT, Aguilar AL, Brown K, Lewis DJ, Jablonski MR, Greden JF. Combinatorial Pharmacogenomic Algorithm is Predictive of Citalopram and Escitalopram Metabolism in Patients with Major Depressive Disorder. Psychiatry Res. 2020 08; 290:113017.
    View in: PubMed
    Score: 0.153
  12. Rothschild AJ. New directions in the treatment of antidepressant-induced sexual dysfunction. Clin Ther. 2000; 22 Suppl A:A42-57; discussion A58-61.
    View in: PubMed
    Score: 0.149
  13. Rothschild AJ. Sexual side effects of antidepressants. J Clin Psychiatry. 2000; 61 Suppl 11:28-36.
    View in: PubMed
    Score: 0.149
  14. Thase ME, Parikh SV, Rothschild AJ, Dunlop BW, DeBattista C, Conway CR, Forester BP, Mondimore FM, Shelton RC, Macaluso M, Li J, Brown K, Jablonski MR, Greden JF. Impact of Pharmacogenomics on Clinical Outcomes for Patients Taking Medications With Gene-Drug Interactions in a Randomized Controlled Trial. J Clin Psychiatry. 2019 10 31; 80(6).
    View in: PubMed
    Score: 0.147
  15. Gunduz-Bruce H, Silber C, Kaul I, Rothschild AJ, Riesenberg R, Sankoh AJ, Li H, Lasser R, Zorumski CF, Rubinow DR, Paul SM, Jonas J, Doherty JJ, Kanes SJ. Trial of SAGE-217 in Patients with Major Depressive Disorder. N Engl J Med. 2019 09 05; 381(10):903-911.
    View in: PubMed
    Score: 0.145
  16. Greden JF, Parikh SV, Rothschild AJ, Thase ME, Dunlop BW, DeBattista C, Conway CR, Forester BP, Mondimore FM, Shelton RC, Macaluso M, Li J, Brown K, Gilbert A, Burns L, Jablonski MR, Dechairo B. Impact of pharmacogenomics on clinical outcomes in major depressive disorder in the GUIDED trial: A large, patient- and rater-blinded, randomized, controlled study. J Psychiatr Res. 2019 04; 111:59-67.
    View in: PubMed
    Score: 0.139
  17. Byrne SE, Rothschild AJ. Loss of antidepressant efficacy during maintenance therapy: possible mechanisms and treatments. J Clin Psychiatry. 1998 Jun; 59(6):279-88.
    View in: PubMed
    Score: 0.133
  18. Byrne S, Rothschild AJ. Psychiatrists' responses to failure of maintenance therapy with antidepressants. Psychiatr Serv. 1997 Jun; 48(6):835-7.
    View in: PubMed
    Score: 0.124
  19. Rothschild AJ. The diagnosis and treatment of late-life depression. J Clin Psychiatry. 1996; 57 Suppl 5:5-11.
    View in: PubMed
    Score: 0.113
  20. Rothschild AJ, Raskin J, Wang CN, Marangell LB, Fava M. The relationship between change in apathy and changes in cognition and functional outcomes in currently non-depressed SSRI-treated patients with major depressive disorder. Compr Psychiatry. 2014 Jan; 55(1):1-10.
    View in: PubMed
    Score: 0.097
  21. Flint AJ, Iaboni A, Mulsant BH, Rothschild AJ, Whyte EM, Meyers BS. Effect of sertraline on risk of falling in older adults with psychotic depression on olanzapine: results of a randomized placebo-controlled trial. Am J Geriatr Psychiatry. 2014 Apr; 22(4):332-6.
    View in: PubMed
    Score: 0.094
  22. Flint AJ, Meyers BS, Rothschild AJ, Whyte EM, Mulsant BH, Rudorfer MV, Marino P. Sustaining remission of psychotic depression: rationale, design and methodology of STOP-PD II. BMC Psychiatry. 2013 Jan 25; 13:38.
    View in: PubMed
    Score: 0.092
  23. Blumberger DM, Mulsant BH, Emeremni C, Houck P, Andreescu C, Mazumdar S, Whyte E, Rothschild AJ, Flint AJ, Meyers BS. Impact of prior pharmacotherapy on remission of psychotic depression in a randomized controlled trial. J Psychiatr Res. 2011 Jul; 45(7):896-901.
    View in: PubMed
    Score: 0.080
  24. Dunlop BW, Li T, Kornstein SG, Friedman ES, Rothschild AJ, Pedersen R, Ninan P, Keller M. Correlation between patient and clinician assessments of depression severity in the PREVENT study. Psychiatry Res. 2010 May 15; 177(1-2):177-83.
    View in: PubMed
    Score: 0.076
  25. Smith E, Rothschild AJ, Heo M, Peasley-Miklus C, Caswell M, Papademetriou E, Flint AJ, Mulsant BH, Meyers BS. Weight gain during olanzapine treatment for psychotic depression: effects of dose and age. Int Clin Psychopharmacol. 2008 May; 23(3):130-7.
    View in: PubMed
    Score: 0.066
  26. Andreescu C, Mulsant BH, Peasley-Miklus C, Rothschild AJ, Flint AJ, Heo M, Caswell M, Whyte EM, Meyers BS. Persisting low use of antipsychotics in the treatment of major depressive disorder with psychotic features. J Clin Psychiatry. 2007 Feb; 68(2):194-200.
    View in: PubMed
    Score: 0.061
  27. Sit D, Rothschild AJ, Creinin MD, Hanusa BH, Wisner KL. Psychiatric outcomes following medical and surgical abortion. Hum Reprod. 2007 Mar; 22(3):878-84.
    View in: PubMed
    Score: 0.060
  28. Ihaddadene RA, Alexopoulos GS, Marino P, Meyers BS, Mulsant BH, Neufeld NH, Rothschild AJ, Voineskos AN, Whyte EM, Flint AJ, Bingham KS. Predictors of attrition during acute pharmacotherapy of psychotic depression in a clinical trial. Psychiatry Res. 2024 Dec; 342:116192.
    View in: PubMed
    Score: 0.052
  29. Kramer MS, Winokur A, Kelsey J, Preskorn SH, Rothschild AJ, Snavely D, Ghosh K, Ball WA, Reines SA, Munjack D, Apter JT, Cunningham L, Kling M, Bari M, Getson A, Lee Y. Demonstration of the efficacy and safety of a novel substance P (NK1) receptor antagonist in major depression. Neuropsychopharmacology. 2004 Feb; 29(2):385-92.
    View in: PubMed
    Score: 0.049
  30. Perivolaris A, Ainsworth NJ, Alexopoulos GS, Bingham KS, Flint AJ, Marino P, Neufeld NH, Rothschild AJ, Voineskos AN, Whyte EM, Mulsant BH. Placebo Effect in Randomized Trials of Major Depressive Disorder With Psychotic Features: A Systematic Review and Descriptive Meta-Analysis. J Clin Psychopharmacol. 2022 Sep-Oct 01; 42(5):489-494.
    View in: PubMed
    Score: 0.045
  31. Patel DA, Flint AJ, Rothschild AJ, Whyte EM, Meyers BS, Mulsant BH, Voineskos AN, Marino P, Alexopoulos GS. Pharmacotherapy Prescriptions for Relapse Prevention of Psychotic Depression After Electroconvulsive Therapy. J Clin Psychopharmacol. 2021 Mar-Apr 01; 41(2):196-199.
    View in: PubMed
    Score: 0.040
  32. Flint AJ, Meyers BS, Rothschild AJ, Whyte EM, Alexopoulos GS, Rudorfer MV, Marino P, Banerjee S, Pollari CD, Wu Y, Voineskos AN, Mulsant BH. Effect of Continuing Olanzapine vs Placebo on Relapse Among Patients With Psychotic Depression in Remission: The STOP-PD II Randomized Clinical Trial. JAMA. 2019 08 20; 322(7):622-631.
    View in: PubMed
    Score: 0.036
  33. Moore BE, Rothschild AJ. Treatment of antidepressant-induced sexual dysfunction. Hosp Pract (1995). 1999 Jan 15; 34(1):89-91, 95-6.
    View in: PubMed
    Score: 0.035
  34. Bingham KS, Meyers BS, Mulsant BH, Rothschild AJ, Whyte EM, Banerjee S, Artis AS, Alexopoulos GS, Flint AJ. Stabilization treatment of remitted psychotic depression: the STOP-PD study. Acta Psychiatr Scand. 2018 09; 138(3):267-273.
    View in: PubMed
    Score: 0.034
  35. Victoria LW, Whyte EM, Butters MA, Meyers BS, Alexopoulos GS, Mulsant BH, Rothschild AJ, Banerjee S, Flint AJ. Improvement in Depression is Associated with Improvement in Cognition in Late-Life Psychotic Depression. Am J Geriatr Psychiatry. 2017 Jun; 25(6):672-679.
    View in: PubMed
    Score: 0.030
  36. Rothschild AJ. Management of psychotic, treatment-resistant depression. Psychiatr Clin North Am. 1996 Jun; 19(2):237-52.
    View in: PubMed
    Score: 0.029
  37. ?stergaard SD, Rothschild AJ, Flint AJ, Mulsant BH, Whyte EM, Vermeulen T, Bech P, Meyers BS. Establishing the cut-off score for remission and severity-ranges on the Psychotic Depression Assessment Scale (PDAS). J Affect Disord. 2016 Jan 15; 190:111-114.
    View in: PubMed
    Score: 0.028
  38. Bingham KS, Whyte EM, Meyers BS, Mulsant BH, Rothschild AJ, Banerjee S, Flint AJ. Relationship Between Cerebrovascular Risk, Cognition, and Treatment Outcome in Late-Life Psychotic Depression. Am J Geriatr Psychiatry. 2015 Dec; 23(12):1270-1275.
    View in: PubMed
    Score: 0.027
  39. Rothschild AJ. Advances in the management of depression: implications for the obstetrician/gynecologist. Am J Obstet Gynecol. 1995 Aug; 173(2):659-66.
    View in: PubMed
    Score: 0.027
  40. Davies SJ, Mulsant BH, Flint AJ, Rothschild AJ, Whyte EM, Meyers BS. Differential impact of anxiety symptoms and anxiety disorders on treatment outcome for psychotic depression in the STOP-PD study. Compr Psychiatry. 2014 Jul; 55(5):1069-76.
    View in: PubMed
    Score: 0.025
  41. Blumberger DM, Mulsant BH, Kanellopoulos D, Whyte EM, Rothschild AJ, Flint AJ, Meyers BS. The incidence of tardive dyskinesia in the study of pharmacotherapy for psychotic depression. J Clin Psychopharmacol. 2013 Jun; 33(3):391-7.
    View in: PubMed
    Score: 0.024
  42. Rothschild AJ. Biology of depression. Med Clin North Am. 1988 Jul; 72(4):765-90.
    View in: PubMed
    Score: 0.017
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.